Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Lange

Gastroenterology Raleigh, NC Medical Doctor

NPI 1487033999 CMS profile 5220317

2601 Lake Dr Ste 201, Raleigh, NC 27607

Open in the dashboard

General payments

$6,514

198 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Lange of Raleigh, NC is reported in the CMS Open Payments database as having received $6,514 across 198 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $958 49
2024 General $3,879 75
2023 General $1,136 52
2022 General $405 20
2019 General $137 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Lange
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Andrew Lange were reported at $958. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Andrew Lange Gastroenterology median Middle half National median
2019 $137 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $405 $448 $129–$1,270 $149
2023 $1,136 $533 $150–$1,390 $160
2024 $3,879 $605 $160–$1,606 $164
2025 $958 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $2,706 14 payments
  2. AbbVie, Inc. $778 48 payments
  3. Genzyme Corporation $441 15 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $326 16 payments
  5. Janssen Biotech, Inc. $301 12 payments
  6. Celgene Corporation $243 14 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $240 13 payments
  8. Intercept Pharmaceuticals, Inc. $221 13 payments
  9. Pfizer Inc. $155 7 payments
  10. Ferring Pharmaceuticals Inc. $154 2 payments
  11. Other $949 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,952 195 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,443 1 payment
  3. Education $119 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $2,615 10 payments
  2. RINVOQ $424 25 payments
  3. DUPIXENT Immunology $419 14 payments
  4. XIFAXAN $272 13 payments
  5. LINZESS $259 17 payments
  6. CREON $258 17 payments
  7. ZEPOSIA $243 14 payments
  8. OCALIVA $221 13 payments
  9. SKYRIZI $210 12 payments
  10. STELARA $205 7 payments
  11. Other $2,194 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

567

Median for Gastroenterology: 569

Drug cost

$341,632

Median for Gastroenterology: $104,976

Branded share of claims

45.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi On-Body Risankizumab-Rzaa Brand 12 $263,186
Xifaxan Rifaximin Brand 12 $36,229
Linzess Linaclotide Brand 31 $25,363
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 49 $3,320
Colesevelam Hcl Generic 22 $3,155
Dexlansoprazole Dr Dexlansoprazole Brand 11 $2,960
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 63 $1,343
Colestipol Hcl Generic 11 $1,335
Budesonide Ec Budesonide Brand 12 $1,142
Pantoprazole Sodium Generic 75 $955

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$133,903

Of which drugs: $77,423

Medicare patients

243

Average age 72

Services billed

5,271

131 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 46%
Ischemic heart disease 28%
Depression 27%
Diabetes 23%
Chronic kidney disease 19%
Cancer 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $2,561
  • GENZYME CORPORATION $165
$2,726 — —
ZEPOSIA
  • Celgene Corporation $135
$135 — —
VELSIPITY
  • PFIZER INC. $111
$111 — —
OCALIVA
  • INTERCEPT PHARMACEUTICALS, INC. $84
$84 — —
CREON
  • AbbVie, Inc. $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

198 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record